Cargando…

Crossroads of Antimicrobial and Diagnostic Stewardship: Assessing Risks to Develop Clinical Decision Support to Combat Multidrug-Resistant Pseudomonas

BACKGROUND: Early detection of multidrug-resistant Pseudomonas aeruginosa (MDRP) remains challenging. Existing risk prediction tools are difficult to translate to bedside application. The goal of this study was to develop a simple electronic medical record (EMR)–integrated tool for prediction of MDR...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Iris, Abate, Daniel, Newman, Michelle, Heil, Emily L, Leekha, Surbhi, Claeys, Kimberly C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603593/
https://www.ncbi.nlm.nih.gov/pubmed/37901124
http://dx.doi.org/10.1093/ofid/ofad512
_version_ 1785126636520210432
author Zou, Iris
Abate, Daniel
Newman, Michelle
Heil, Emily L
Leekha, Surbhi
Claeys, Kimberly C
author_facet Zou, Iris
Abate, Daniel
Newman, Michelle
Heil, Emily L
Leekha, Surbhi
Claeys, Kimberly C
author_sort Zou, Iris
collection PubMed
description BACKGROUND: Early detection of multidrug-resistant Pseudomonas aeruginosa (MDRP) remains challenging. Existing risk prediction tools are difficult to translate to bedside application. The goal of this study was to develop a simple electronic medical record (EMR)–integrated tool for prediction of MDRP infection. METHODS: This was a mixed-methods study. We conducted a split-sample cohort study of adult critical care patients with P aeruginosa infections. Two previously published tools were validated using c-statistic. A subset of variables based on strength of association and ease of EMR extraction was selected for further evaluation. A simplified tool was developed using multivariable logistic regression. Both c-statistic and theoretical trade-off of over- versus underprescribing of broad-spectrum MDRP therapy were assessed in the validation cohort. A qualitative survey of frontline clinicians assessed understanding of risks for MDRP and potential usability of an EMR-integrated tool to predict MDRP. RESULTS: The 2 previous risk prediction tools demonstrated similar accuracy in the derivation cohort (c-statistic of 0.76 [95% confidence interval {CI}, .69–.83] and 0.73 [95% CI, .66–.8]). A simplified tool based on 4 variables demonstrated reasonable accuracy (c-statistic of 0.71 [95% CI, .57–.85]) without significant overprescribing in the validation cohort. The risk factors were prior MDRP infection, ≥4 antibiotics prior to culture, infection >3 days after admission, and dialysis. Fourteen clinicians completed the survey. An alert providing context regarding individual patient risk factors for MDRP was preferred. CONCLUSIONS: These results can be used to develop a local EMR-integrated tool to improve timeliness of effective therapy in those at risk of MDRP infections.
format Online
Article
Text
id pubmed-10603593
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106035932023-10-28 Crossroads of Antimicrobial and Diagnostic Stewardship: Assessing Risks to Develop Clinical Decision Support to Combat Multidrug-Resistant Pseudomonas Zou, Iris Abate, Daniel Newman, Michelle Heil, Emily L Leekha, Surbhi Claeys, Kimberly C Open Forum Infect Dis Major Article BACKGROUND: Early detection of multidrug-resistant Pseudomonas aeruginosa (MDRP) remains challenging. Existing risk prediction tools are difficult to translate to bedside application. The goal of this study was to develop a simple electronic medical record (EMR)–integrated tool for prediction of MDRP infection. METHODS: This was a mixed-methods study. We conducted a split-sample cohort study of adult critical care patients with P aeruginosa infections. Two previously published tools were validated using c-statistic. A subset of variables based on strength of association and ease of EMR extraction was selected for further evaluation. A simplified tool was developed using multivariable logistic regression. Both c-statistic and theoretical trade-off of over- versus underprescribing of broad-spectrum MDRP therapy were assessed in the validation cohort. A qualitative survey of frontline clinicians assessed understanding of risks for MDRP and potential usability of an EMR-integrated tool to predict MDRP. RESULTS: The 2 previous risk prediction tools demonstrated similar accuracy in the derivation cohort (c-statistic of 0.76 [95% confidence interval {CI}, .69–.83] and 0.73 [95% CI, .66–.8]). A simplified tool based on 4 variables demonstrated reasonable accuracy (c-statistic of 0.71 [95% CI, .57–.85]) without significant overprescribing in the validation cohort. The risk factors were prior MDRP infection, ≥4 antibiotics prior to culture, infection >3 days after admission, and dialysis. Fourteen clinicians completed the survey. An alert providing context regarding individual patient risk factors for MDRP was preferred. CONCLUSIONS: These results can be used to develop a local EMR-integrated tool to improve timeliness of effective therapy in those at risk of MDRP infections. Oxford University Press 2023-10-12 /pmc/articles/PMC10603593/ /pubmed/37901124 http://dx.doi.org/10.1093/ofid/ofad512 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Major Article
Zou, Iris
Abate, Daniel
Newman, Michelle
Heil, Emily L
Leekha, Surbhi
Claeys, Kimberly C
Crossroads of Antimicrobial and Diagnostic Stewardship: Assessing Risks to Develop Clinical Decision Support to Combat Multidrug-Resistant Pseudomonas
title Crossroads of Antimicrobial and Diagnostic Stewardship: Assessing Risks to Develop Clinical Decision Support to Combat Multidrug-Resistant Pseudomonas
title_full Crossroads of Antimicrobial and Diagnostic Stewardship: Assessing Risks to Develop Clinical Decision Support to Combat Multidrug-Resistant Pseudomonas
title_fullStr Crossroads of Antimicrobial and Diagnostic Stewardship: Assessing Risks to Develop Clinical Decision Support to Combat Multidrug-Resistant Pseudomonas
title_full_unstemmed Crossroads of Antimicrobial and Diagnostic Stewardship: Assessing Risks to Develop Clinical Decision Support to Combat Multidrug-Resistant Pseudomonas
title_short Crossroads of Antimicrobial and Diagnostic Stewardship: Assessing Risks to Develop Clinical Decision Support to Combat Multidrug-Resistant Pseudomonas
title_sort crossroads of antimicrobial and diagnostic stewardship: assessing risks to develop clinical decision support to combat multidrug-resistant pseudomonas
topic Major Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603593/
https://www.ncbi.nlm.nih.gov/pubmed/37901124
http://dx.doi.org/10.1093/ofid/ofad512
work_keys_str_mv AT zouiris crossroadsofantimicrobialanddiagnosticstewardshipassessingriskstodevelopclinicaldecisionsupporttocombatmultidrugresistantpseudomonas
AT abatedaniel crossroadsofantimicrobialanddiagnosticstewardshipassessingriskstodevelopclinicaldecisionsupporttocombatmultidrugresistantpseudomonas
AT newmanmichelle crossroadsofantimicrobialanddiagnosticstewardshipassessingriskstodevelopclinicaldecisionsupporttocombatmultidrugresistantpseudomonas
AT heilemilyl crossroadsofantimicrobialanddiagnosticstewardshipassessingriskstodevelopclinicaldecisionsupporttocombatmultidrugresistantpseudomonas
AT leekhasurbhi crossroadsofantimicrobialanddiagnosticstewardshipassessingriskstodevelopclinicaldecisionsupporttocombatmultidrugresistantpseudomonas
AT claeyskimberlyc crossroadsofantimicrobialanddiagnosticstewardshipassessingriskstodevelopclinicaldecisionsupporttocombatmultidrugresistantpseudomonas